TB-500 for Eyes: What the Evidence Shows
What human and animal studies show about TB-500 for eyes, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 2
- with an outcome for eyes, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- 1
- with an outcome for eyes, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 3
- with an outcome for eyes
Evidence for eyes
Each row is an outcome related to eyes from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Ocular discomfort and corneal staining | At day 56, the treated group had a 35.1% greater reduction in ocular discomfort and a 59.1% greater reduction in total corneal fluorescein staining than vehicle (very small trial). | Human RCTn = 9 | Cornea 2015, PMID 25826322 |
| Primary endpoints | Neither primary endpoint (ocular discomfort, inferior corneal staining) differed significantly between groups. | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| Secondary endpoints | Discomfort scores in the challenge environment on day 28 were 27% lower than placebo (P=0.0244), a secondary endpoint. | Human RCTn = 72 | Clinical ophthalmology 2015, PMID 26056426 |
| Corneal alkali burn | The peptide-containing hydrogel accelerated corneal epithelial regeneration and reduced inflammation in an alkali burn model; this is a formulation study. | Animal · human corneal cells in vitro plus an animal alkali burn model (species not stated in abstract) (not a human result) | ACS applied materials & interfaces 2025, PMID 41359360 |
TB-500 and eyes are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
The goal in plain terms
MedlinePlus describes eye care as keeping eyes healthy through daily habits, checkups and treatment when needed.[4]
What was measured that is closest
In a nine-patient severe dry eye trial of full-length thymosin beta-4 eye drops (not TB-500), symptom and sign scores differed from vehicle at several time points.[1]
The larger 72-subject trial missed both primary endpoints but reported significant differences on some secondary endpoints.[2]
In human corneal cells and an alkali-burn animal model, a hydrogel built with the TB500 sequence sped epithelial regeneration. No person was treated.[3]
Safety in the eye studies
The authors of the 72-subject trial reported no adverse events by any subject.[2]
Other peptides people research for eyes
All peptides for eyes, comparedCommon questions
Does TB-500 help with eyes?
The strongest study we summarise for eyes is human rct evidence, across 3 studies with an outcome for eyes. A trial result is not an approval; see the legal status.
Is TB-500 approved for eyes?
No. TB-500 is not FDA approved for any use, including eyes.
What is the best peptide for eyes?
There is no single answer. Our eyes overview compares each candidate by evidence grade and legal status rather than by popularity.
Is TB-500 used for eyes?
Eye work used full-length thymosin beta-4 drops in people and a TB500-sequence hydrogel in cells and animals; no study gave TB-500 injections for eye outcomes.
Calculated from human eye trials 2; tb500 injection eye studies 0. Formula: human eye trials cited = 2 (the nine-patient and the 72-subject dry-eye trials); TB-500 injection eye studies = 0
More on TB-500
Sources
- 1Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.Cornea · 2015PMID 25826322Accessed 2 Oct 2026
- 2Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.Clinical ophthalmology (Auckland, N.Z.) · 2015PMID 26056426Accessed 2 Oct 2026
- 3Alkaline Phosphatase-Triggered Spatiotemporal Repair of Corneal Injury with TB500 Peptide Hydrogel.ACS applied materials & interfaces · 2025PMID 41359360Accessed 2 Oct 2026
- 4Official web pageOfficial web page · web page
Found an error? Report a correction.